Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD
ZUG, Switzerland, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Covis Pharma Group ("Covis"), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening conditions
Republic Of Kostenloser Wertpapierhandel Covis Pharma Covis Pharma Group Drug Administration Pharma Group
Source: finanznachrichten.de